Clinical Trials Browser

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT02653118 2024-11-12

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Active not recruiting

4,453 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Recruiting

8,000 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05371353 2024-04-17

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Recruiting

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05584332 2023-07-21

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Terminated

3,131 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Phase 1 Completed

90 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Phase 2 Completed

780 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase 1 Completed

160 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04425291 2022-02-25

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,680 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04073082 2019-08-30

Safety and Efficacy of Laser Therapy in Gynaecology

Unknown

300 enrolled

Gynecologic

Uterine Cervical Dysplasia, Condylomata Acuminata, Herpes Genitalis, Hidradenitis Suppurativa, Lichen Sclerosus et Atrophicus

NCT01047345 2018-11-27

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Phase 3 Completed

924 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092482 2017-03-22

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Phase 3 Completed

3,882 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00517309 2017-03-22

FUTURE

Phase 3 Completed

1,877 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00851643 2016-02-03

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Phase 1 Completed

158 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT00520598 2015-11-26

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Phase 2 Completed

511 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092521 2015-09-25

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Phase 3 Completed

5,759 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00365443 2015-06-19

Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

Phase 2 Withdrawn

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Phase 2 Completed

620 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00092495 2015-01-13

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Phase 3 Completed

3,055 enrolled 25 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

Clinical Trials

FUTURE II

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

V503-017

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Safety and Efficacy of Laser Therapy in Gynaecology

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

FUTURE

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)